You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Rheumatoid arthritis
Cimzia is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult
patients.
Combined with MTX in case of either an inadequate response or intolerance to previous
therapy with one or more disease modifying antirheumatic drugs (DMARDs) or
As monotherapy in case of a contraindication or intolerance to MTX (see Section 4.2 Dose
and Method of Administration).
Cimzia has been shown to reduce the rate of progression of joint damage as measured by X-ray, when
given in combination with MTX.
Cimzia in combination with MTX is indicated for the treatment of severe, active and progressive
rheumatoid arthritis in adults not previously treated with MTX or other DMARDs.
Psoriatic arthritis
Cimzia is indicated for the treatment of adult patients with active psoriatic arthritis where response to
previous disease modifying antirheumatic drug therapy (DMARDs) has been inadequate. Cimzia has
been shown to improve physical function.,Ankylosing spondylitis
Cimzia is indicated for the treatment of adult patients with active, ankylosing spondylitis who have
been intolerant to or have had inadequate response to at least one nonsteroidal anti-inflammatory drug
(NSAID).,Non-radiographic Axial Spondyloarthritis
Cimzia is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis
(nr-axSpA) with objective signs of inflammation as indicated by elevated C reactive protein (CRP)
and /or magnetic resonance imaging (MRI) change, who have had an inadequate response to, or are
intolerant to, nonsteroidal anti-inflammatory drugs (NSAIDs).,Plaque psoriasis
Cimzia is indicated for the treatment of adult patients with moderate to severe chronic plaque
psoriasis who are candidates for systemic therapy or phototherapy.
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on May, 1 2025. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Rheumatoid arthritis
Cimzia is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult
patients.
Combined with MTX in case of either an inadequate response or intolerance to previous
therapy with one or more disease modifying antirheumatic drugs (DMARDs) or
As monotherapy in case of a contraindication or intolerance to MTX (see Section 4.2 Dose
and Method of Administration).
Cimzia has been shown to reduce the rate of progression of joint damage as measured by X-ray, when
given in combination with MTX.
Cimzia in combination with MTX is indicated for the treatment of severe, active and progressive
rheumatoid arthritis in adults not previously treated with MTX or other DMARDs.,Psoriatic arthritis
Cimzia is indicated for the treatment of adult patients with active psoriatic arthritis where response to
previous disease modifying antirheumatic drug therapy (DMARDs) has been inadequate. Cimzia has
been shown to improve physical function.,Ankylosing spondylitis
Cimzia is indicated for the treatment of adult patients with active, ankylosing spondylitis who have
been intolerant to or have had inadequate response to at least one nonsteroidal anti-inflammatory drug
(NSAID).,Non-radiographic Axial Spondyloarthritis
Cimzia is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis
(nr-axSpA) with objective signs of inflammation as indicated by elevated C reactive protein (CRP)
and /or magnetic resonance imaging (MRI) change, who have had an inadequate response to, or are
intolerant to, nonsteroidal anti-inflammatory drugs (NSAIDs).,Plaque psoriasis
Cimzia is indicated for the treatment of adult patients with moderate to severe chronic plaque
psoriasis who are candidates for systemic therapy or phototherapy.
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on May, 1 2025. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Rheumatoid arthritis
Cimzia is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult
patients.
Combined with MTX in case of either an inadequate response or intolerance to previous
therapy with one or more disease modifying antirheumatic drugs (DMARDs) or
As monotherapy in case of a contraindication or intolerance to MTX (see Section 4.2 Dose
and Method of Administration).
Cimzia has been shown to reduce the rate of progression of joint damage as measured by X-ray, when
given in combination with MTX.
Cimzia in combination with MTX is indicated for the treatment of severe, active and progressive
rheumatoid arthritis in adults not previously treated with MTX or other DMARDs.,Psoriatic arthritis
Cimzia is indicated for the treatment of adult patients with active psoriatic arthritis where response to
previous disease modifying antirheumatic drug therapy (DMARDs) has been inadequate. Cimzia has
been shown to improve physical function.,Ankylosing spondylitis
Cimzia is indicated for the treatment of adult patients with active, ankylosing spondylitis who have
been intolerant to or have had inadequate response to at least one nonsteroidal anti-inflammatory drug
(NSAID).,Non-radiographic Axial Spondyloarthritis
Cimzia is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis
(nr-axSpA) with objective signs of inflammation as indicated by elevated C reactive protein (CRP)
and /or magnetic resonance imaging (MRI) change, who have had an inadequate response to, or are
intolerant to, nonsteroidal anti-inflammatory drugs (NSAIDs).,Plaque psoriasis
Cimzia is indicated for the treatment of adult patients with moderate to severe chronic plaque
psoriasis who are candidates for systemic therapy or phototherapy.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Rheumatoid arthritis
Cimzia is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult
patients.
Combined with MTX in case of either an inadequate response or intolerance to previous
therapy with one or more disease modifying antirheumatic drugs (DMARDs) or
As monotherapy in case of a contraindication or intolerance to MTX (see Section 4.2 Dose
and Method of Administration).
Cimzia has been shown to reduce the rate of progression of joint damage as measured by X-ray, when
given in combination with MTX.
Cimzia in combination with MTX is indicated for the treatment of severe, active and progressive
rheumatoid arthritis in adults not previously treated with MTX or other DMARDs.,Psoriatic arthritis
Cimzia is indicated for the treatment of adult patients with active psoriatic arthritis where response to
previous disease modifying antirheumatic drug therapy (DMARDs) has been inadequate. Cimzia has
been shown to improve physical function.,Ankylosing spondylitis
Cimzia is indicated for the treatment of adult patients with active, ankylosing spondylitis who have
been intolerant to or have had inadequate response to at least one nonsteroidal anti-inflammatory drug
(NSAID).,Non-radiographic Axial Spondyloarthritis
Cimzia is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis
(nr-axSpA) with objective signs of inflammation as indicated by elevated C reactive protein (CRP)
and /or magnetic resonance imaging (MRI) change, who have had an inadequate response to, or are
intolerant to, nonsteroidal anti-inflammatory drugs (NSAIDs).,Plaque psoriasis
Cimzia is indicated for the treatment of adult patients with moderate to severe chronic plaque
psoriasis who are candidates for systemic therapy or phototherapy.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Government Accredited with over 140 information partners
We are a government-funded service, providing quality, approved health information and advice
Healthdirect Australia acknowledges the Traditional Owners of Country throughout Australia and their continuing
connection to land, sea and community. We pay our respects to the Traditional Owners and to Elders both past and
present.
